Neurogene (NGNE) Equity Ratio (2013 - 2026)

Neurogene has reported Equity Ratio for 14 years, with the latest figure at 0.9 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 2.36% year-over-year to 0.9; the trailing twelve-month figure through Mar 2026 stood at 0.9 (down 2.36% YoY), and the FY2025 full-year result was 0.92, down 0.72% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.9, down from 0.92 in the prior quarter.
• The five-year high for Equity Ratio was 0.93 in Q1 2025, with the low at 2.05 in Q3 2023.
• Historically, Equity Ratio has averaged 0.28 across 5 years, with a median of 0.86 in 2024.
• The largest YoY upside for Equity Ratio was 162.66% in 2023 against a maximum downside of 345.02% in 2023.
• Neurogene's Equity Ratio stood at 1.33 in 2022, then jumped by 162.66% to 0.84 in 2023, then climbed by 10.61% to 0.92 in 2024, then declined by 0.72% to 0.92 in 2025, then declined by 1.55% to 0.9 in 2026.
• The last three Equity Ratio figures came in at 0.9 (Q1 2026), 0.92 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.